COSCIENS Biopharma Inc.

NASDAQ:CSCI USA Biotechnology
Market Cap
$4.80 Million
Market Cap Rank
#31727 Global
#10449 in USA
Share Price
$1.51
Change (1 day)
-15.17%
52-Week Range
$1.39 - $4.35
All Time High
$1143.00
Categories
Companies in USA Biotechnology
About

COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reducti… Read more

COSCIENS Biopharma Inc. (CSCI) - Net Assets

Latest net assets as of June 2025: $7.10 Million USD

Based on the latest financial reports, COSCIENS Biopharma Inc. (CSCI) has net assets worth $7.10 Million USD as of June 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($27.56 Million) and total liabilities ($20.46 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $7.10 Million
% of Total Assets 25.75%
Annual Growth Rate 2.95%
5-Year Change -30.97%
10-Year Change 131.87%
Growth Volatility 389.84

COSCIENS Biopharma Inc. - Net Assets Trend (1996–2024)

This chart illustrates how COSCIENS Biopharma Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for COSCIENS Biopharma Inc. (1996–2024)

The table below shows the annual net assets of COSCIENS Biopharma Inc. from 1996 to 2024.

Year Net Assets Change
2024-12-31 $13.16 Million -37.43%
2023-12-31 $21.04 Million -11.58%
2022-12-31 $23.79 Million +9.43%
2021-12-31 $21.74 Million +14.04%
2020-12-31 $19.06 Million +11.61%
2019-12-31 $17.08 Million +0.21%
2018-12-31 $17.04 Million -4.93%
2017-12-31 $17.93 Million +7.57%
2016-12-31 $16.67 Million +193.62%
2015-12-31 $5.68 Million +214.96%
2014-12-31 $1.80 Million +684.83%
2013-12-31 $229.62K +1584.18%
2012-12-31 $13.63K -97.31%
2011-12-31 $507.11K +177.43%
2010-12-31 $-654.90K +50.05%
2009-12-31 $-1.31 Million +17.38%
2008-12-31 $-1.59 Million -201.14%
2007-12-31 $1.57 Million +501.94%
2006-12-31 $260.64K -34.39%
2005-12-31 $397.23K +318.63%
2004-12-31 $94.89K -67.81%
2003-12-31 $294.75K +171.07%
2002-12-31 $-414.76K +41.94%
2001-12-31 $-714.40K +55.20%
2000-12-31 $-1.59 Million -21.55%
1999-12-31 $-1.31 Million -83.50%
1998-12-31 $-714.89K -110.88%
1997-12-31 $6.57 Million +12.52%
1996-12-31 $5.84 Million --

Equity Component Analysis

This analysis shows how different components contribute to COSCIENS Biopharma Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 415611792.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock $22.49 Million 170.85%
Other Comprehensive Income $-1.48 Million -11.27%
Other Components $4.27 Million 32.43%
Total Equity $13.16 Million 100.00%

COSCIENS Biopharma Inc. Competitors by Market Cap

The table below lists competitors of COSCIENS Biopharma Inc. ranked by their market capitalization.

Company Market Cap
Salutica Bhd
KLSE:0183
 		$4.41 Million
High Peak Royalties Ltd
AU:HPR
 		$4.41 Million
Inception Growth Acquisition Ltd
NASDAQ:IGTA
 		$4.41 Million
LNG Energy Group Corp.
OTCQB:LNGNF
 		$4.41 Million
Gunpoint Exploration Ltd
PINK:CJIMF
 		$4.41 Million
Orcay Ortakoy Cay Sanayi & Ticaret AS
IS:ORCAY
 		$4.40 Million
Desane Group Holdings Ltd
AU:DGH
 		$4.40 Million
Corre Energy BV
IR:CORRE
 		$4.40 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in COSCIENS Biopharma Inc.'s equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 21,035,000 to 13,161,000, a change of -7,874,000 (-37.4%).
  • Net loss of 15,309,000 reduced equity.
  • Other comprehensive income decreased equity by 5,833,626.
  • Other factors increased equity by 13,268,626.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income $-15.31 Million -116.32%
Other Comprehensive Income $-5.83 Million -44.33%
Other Changes $13.27 Million +100.82%
Total Change $- -37.43%

Book Value vs Market Value Analysis

This analysis compares COSCIENS Biopharma Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.30x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has increased from 0.11x to 0.30x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1996-12-31 $13.37 $1.51 x
1997-12-31 $17.85 $1.51 x
1998-12-31 $-1.67 $1.51 x
1999-12-31 $-2.47 $1.51 x
2000-12-31 $-3.18 $1.51 x
2001-12-31 $-1.03 $1.51 x
2002-12-31 $-0.61 $1.51 x
2003-12-31 $0.37 $1.51 x
2004-12-31 $0.10 $1.51 x
2005-12-31 $0.46 $1.51 x
2006-12-31 $0.30 $1.51 x
2007-12-31 $1.57 $1.51 x
2008-12-31 $-1.43 $1.51 x
2009-12-31 $-1.12 $1.51 x
2010-12-31 $-0.52 $1.51 x
2011-12-31 $0.38 $1.51 x
2012-12-31 $0.01 $1.51 x
2013-12-31 $0.16 $1.51 x
2014-12-31 $1.22 $1.51 x
2015-12-31 $3.69 $1.51 x
2016-12-31 $9.90 $1.51 x
2017-12-31 $10.08 $1.51 x
2018-12-31 $9.48 $1.51 x
2019-12-31 $9.38 $1.51 x
2020-12-31 $10.34 $1.51 x
2021-12-31 $11.72 $1.51 x
2022-12-31 $12.83 $1.51 x
2023-12-31 $11.39 $1.51 x
2024-12-31 $5.10 $1.51 x

Capital Efficiency Dashboard

This dashboard shows how efficiently COSCIENS Biopharma Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -116.32%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -111.07%
  • • Asset Turnover: 0.39x
  • • Equity Multiplier: 2.66x
  • Recent ROE (-116.32%) is above the historical average (-152.47%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1996 -46.25% -616.67% 0.03x 2.33x $-3.28 Million
1997 -210.64% -860.87% 0.18x 1.39x $-14.49 Million
1998 0.00% -3575.01% 0.80x 0.00x $-9.22 Million
1999 0.00% -275.76% 1.12x 0.00x $-490.22K
2000 0.00% -113.23% 2.75x 0.00x $-451.35K
2001 0.00% -30.11% 3.08x 0.00x $-145.96K
2002 0.00% 7.78% 2.30x 0.00x $115.02K
2003 115.65% 19.93% 1.77x 3.28x $311.40K
2004 -348.69% -20.32% 1.14x 15.06x $-340.35K
2005 -12.36% -2.12% 1.11x 5.24x $-88.81K
2006 -89.65% -8.23% 1.60x 6.79x $-259.73K
2007 -89.42% -40.30% 0.75x 2.95x $-1.56 Million
2008 0.00% -85.13% 1.29x 0.00x $-2.80 Million
2009 0.00% -1.59% 1.58x 0.00x $64.87K
2010 0.00% 8.32% 1.98x 0.00x $529.14K
2011 111.55% 9.98% 1.39x 8.06x $514.98K
2012 -3969.13% -10.42% 1.33x 286.50x $-542.51K
2013 71.91% 2.69% 1.28x 20.85x $142.15K
2014 76.18% 17.93% 1.16x 3.67x $1.19 Million
2015 62.49% 46.14% 0.68x 1.99x $2.98 Million
2016 16.16% 26.47% 0.52x 1.18x $1.03 Million
2017 -4.25% -7.41% 0.46x 1.23x $-2.55 Million
2018 -1.36% -2.72% 0.46x 1.09x $-1.94 Million
2019 -5.08% -8.79% 0.47x 1.22x $-2.58 Million
2020 7.64% 12.27% 0.52x 1.20x $-450.84K
2021 12.14% 19.57% 0.55x 1.12x $465.44K
2022 14.49% 23.66% 0.52x 1.17x $1.07 Million
2023 -16.57% -48.79% 0.30x 1.13x $-5.59 Million
2024 -116.32% -111.07% 0.39x 2.66x $-16.63 Million

Industry Comparison

This section compares COSCIENS Biopharma Inc.'s net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $59,082,939
  • Average return on equity (ROE) among peers: -341.19%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
COSCIENS Biopharma Inc. (CSCI) $7.10 Million -46.25% 2.88x $4.41 Million
Aadi Bioscience Inc (AADI) $-124.24K 0.00% 0.00x $17.03 Million
America Great Health (AAGH) $-992.37K 0.00% 0.00x $2.12 Million
Ascentage Pharma Group International (AAPG) $70.63 Million -1310.51% 34.40x $2.25 Billion
Aardvark Therapeutics, Inc. Common Stock (AARD) $-27.92 Million 0.00% 0.00x $59.18 Million
ABIVAX Société Anonyme (AAVXF) $196.01 Million -75.37% 0.67x $377.86 Million
Abcellera Biologics Inc (ABCL) $10.25 Million -21.57% 1.29x $738.02 Million
Abeona Therapeutics Inc (ABEO) $489.00K -1919.02% 38.85x $202.79 Million
Acumen Pharmaceuticals Inc (ABOS) $188.78 Million -22.70% 0.04x $108.65 Million
Abpro Holdings, Inc. (ABP) $-22.46 Million 0.00% 0.00x $2.00 Million
Absci Corp (ABSI) $176.18 Million -62.76% 0.23x $345.85 Million